141 related articles for article (PubMed ID: 1569295)
1. Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma.
Blind E; Raue F; Klaiber T; Zink A; Schroth J; Buhr H; Ziegler R
J Endocrinol Invest; 1992 Feb; 15(2):93-8. PubMed ID: 1569295
[TBL] [Abstract][Full Text] [Related]
2. PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma.
Raue F; Blind E; Grauer A
Henry Ford Hosp Med J; 1992; 40(3-4):296-8. PubMed ID: 1483876
[TBL] [Abstract][Full Text] [Related]
3. PDN-21: possible tumor marker for medullary thyroid carcinoma.
Takami H; Shikata J; Horie H; Sekine K; Ito K
J Surg Oncol; 1990 Aug; 44(4):205-7. PubMed ID: 2385096
[TBL] [Abstract][Full Text] [Related]
4. Calcitonin and PDN-21 as tumour markers in MEN-2 family screening for medullary thyroid carcinoma.
Schifter S
Eur J Cancer; 1992; 28(2-3):341-5. PubMed ID: 1350454
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic evaluation of measurements of carboxyl-terminal flanking peptide (PDN-21) of the human calcitonin gene in human serum.
Ittner J; Dambacher MA; Born W; Ketelslegers JM; Buysschaert M; Albert PM; Lambert AE; Fischer JA
J Clin Endocrinol Metab; 1985 Dec; 61(6):1133-7. PubMed ID: 3902867
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A as tumor marker in medullary thyroid carcinoma.
Blind E; Schmidt-Gayk H; Sinn HP; O'Connor DT; Raue F
Thyroid; 1992; 2(1):5-10. PubMed ID: 1356053
[TBL] [Abstract][Full Text] [Related]
7. Cosecretion of calcitonin gene products: studies with a C18 cartridge extraction method for human plasma PDN-21 (katacalcin).
Hurley DL; Katz HH; Tiegs RD; Calvo MS; Barta JR; Heath H
J Clin Endocrinol Metab; 1988 Mar; 66(3):640-4. PubMed ID: 3350911
[TBL] [Abstract][Full Text] [Related]
8. Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.
Barbot N; Calmettes C; Schuffenecker I; Saint-André JP; Franc B; Rohmer V; Jallet P; Bigorgne JC
J Clin Endocrinol Metab; 1994 Jan; 78(1):114-20. PubMed ID: 7904611
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
Rieu M; Lame MC; Richard A; Lissak B; Sambort B; Vuong-Ngoc P; Berrod JL; Fombeur JP
Clin Endocrinol (Oxf); 1995 May; 42(5):453-60. PubMed ID: 7621562
[TBL] [Abstract][Full Text] [Related]
10. Measurement of serum PDN-21 (Katacalcin) levels by radioimmunoassay in patients with various thyroid diseases.
Takami H
Exp Clin Endocrinol; 1994; 102(5):370-3. PubMed ID: 7867699
[TBL] [Abstract][Full Text] [Related]
11. [Katacalcin--a new tumor marker in C-cell cancer of the thyroid gland].
Raue F; Boden M; Girgis S; Rix E; Ziegler R
Klin Wochenschr; 1987 Jan; 65(2):82-6. PubMed ID: 3550267
[TBL] [Abstract][Full Text] [Related]
12. Ghrelin in human medullary thyroid carcinomas.
Morpurgo PS; Cappiello V; Verga U; Vicentini L; Vaghi I; Lauri E; Nebuloni M; Beck-Peccoz P; Spada A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):437-41. PubMed ID: 16181236
[TBL] [Abstract][Full Text] [Related]
13. Clinical performance of an extraction calcitonin radioimmunoassay.
Kao PC; Gharib H
Mayo Clin Proc; 1993 Dec; 68(12):1165-70. PubMed ID: 8246617
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma.
Perdrisot R; Bigorgne JC; Guilloteau D; Jallet P
Clin Chem; 1990 Feb; 36(2):381-3. PubMed ID: 2302785
[TBL] [Abstract][Full Text] [Related]
15. A comparison of calcium pentagastrin and TRH tests in screening for medullary carcinoma of the thyroid in MEN IIA.
O'Connell JE; Dominiczak AF; Isles CG; McLellan AR; Davidson G; Gray CE; Connell JM
Clin Endocrinol (Oxf); 1990 Apr; 32(4):417-21. PubMed ID: 1971777
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules.
Costante G; Meringolo D; Durante C; Bianchi D; Nocera M; Tumino S; Crocetti U; Attard M; Maranghi M; Torlontano M; Filetti S
J Clin Endocrinol Metab; 2007 Feb; 92(2):450-5. PubMed ID: 17119000
[TBL] [Abstract][Full Text] [Related]
17. Determination of silica-purified plasma calcitonin for the detection and management of medullary thyroid carcinoma: comparison of two provocative tests.
Gharib H; Kao PC; Heath H
Mayo Clin Proc; 1987 May; 62(5):373-8. PubMed ID: 3573825
[TBL] [Abstract][Full Text] [Related]
18. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease.
Herrmann BL; Schmid KW; Goerges R; Kemen M; Mann K
Eur J Endocrinol; 2010 Jun; 162(6):1141-5. PubMed ID: 20332126
[TBL] [Abstract][Full Text] [Related]
19. Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families.
Wion-Barbot N; Schuffenecker I; Niccoli P; Conte-Devolx B; Lecomte P; Houdent C; Bigorgne JC; Modigliani E
Ann Endocrinol (Paris); 1997; 58(4):302-8. PubMed ID: 9436479
[TBL] [Abstract][Full Text] [Related]
20. Determination of plasma calcitonin gene-related peptide concentrations by a new immunochemiluminometric assay in normal persons and patients with medullary thyroid carcinoma and other neuroendocrine tumors.
Carter WB; Taylor RL; Kao PC; Heath H
J Clin Endocrinol Metab; 1991 Feb; 72(2):327-35. PubMed ID: 1991803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
